metformin + orlistat + chiglitazar

This is a combination drug consisting of metformin, orlistat, and chiglitazar. - **Metformin** is a biguanide antihyperglycemic agent that primarily decreases hepatic glucose production and increases insulin sensitivity, widely used as first-line therapy for type 2 diabetes. - **Orlistat** is a gastrointestinal lipase inhibitor that reduces dietary fat absorption by inhibiting pancreatic and gastric lipases, indicated for obesity management. - **Chiglitazar** is an orally administered small-molecule pan-peroxisome proliferator-activated receptor (PPAR) agonist (α, δ, γ), approved in China for glycemic control in adults with type 2 diabetes; it improves insulin sensitivity and modulates lipid metabolism[2][3][5][6]. The combination aims to provide comprehensive metabolic benefits by targeting multiple mechanisms involved in glucose regulation, lipid metabolism, and weight control.